188 related articles for article (PubMed ID: 11686575)
1. Folate, homocysteine, endothelial function and cardiovascular disease. What is the link?
Ashfield-Watt PA; Moat SJ; Doshi SN; McDowell IF
Biomed Pharmacother; 2001 Oct; 55(8):425-33. PubMed ID: 11686575
[TBL] [Abstract][Full Text] [Related]
2. Optimization of dietary folate or low-dose folic acid supplements lower homocysteine but do not enhance endothelial function in healthy adults, irrespective of the methylenetetrahydrofolate reductase (C677T) genotype.
Pullin CH; Ashfield-Watt PA; Burr ML; Clark ZE; Lewis MJ; Moat SJ; Newcombe RG; Powers HJ; Whiting JM; McDowell IF
J Am Coll Cardiol; 2001 Dec; 38(7):1799-805. PubMed ID: 11738277
[TBL] [Abstract][Full Text] [Related]
3. The controversy over homocysteine and cardiovascular risk.
Ueland PM; Refsum H; Beresford SA; Vollset SE
Am J Clin Nutr; 2000 Aug; 72(2):324-32. PubMed ID: 10919921
[TBL] [Abstract][Full Text] [Related]
4. Methylenetetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia, and cardiovascular diseases in chronic hemodialysis patients.
Morimoto K; Haneda T; Okamoto K; Ishida H; Kikuchi K
Nephron; 2002 Jan; 90(1):43-50. PubMed ID: 11744804
[TBL] [Abstract][Full Text] [Related]
5. Effect of MTHFR 677C>T on plasma total homocysteine levels in renal graft recipients.
Födinger M; Wölfl G; Fischer G; Rasoul-Rockenschaub S; Schmid R; Hörl WH; Sunder-Plassmann G
Kidney Int; 1999 Mar; 55(3):1072-80. PubMed ID: 10027946
[TBL] [Abstract][Full Text] [Related]
6. [Hyperhomocysteinemia: an independent risk factor or a simple marker of vascular disease?. 1. Basic data].
Guilland JC; Favier A; Potier de Courcy G; Galan P; Hercberg S
Pathol Biol (Paris); 2003 Mar; 51(2):101-10. PubMed ID: 12801808
[TBL] [Abstract][Full Text] [Related]
7. Folate, homocysteine, endothelial function and cardiovascular disease.
Moat SJ; Lang D; McDowell IF; Clarke ZL; Madhavan AK; Lewis MJ; Goodfellow J
J Nutr Biochem; 2004 Feb; 15(2):64-79. PubMed ID: 14972346
[TBL] [Abstract][Full Text] [Related]
8. Methylenetetrahydrofolate reductase genotype, vitamin B12, and folate influence plasma homocysteine in hemodialysis patients.
Nakamura T; Saionji K; Hiejima Y; Hirayama H; Tago K; Takano H; Tajiri M; Hayashi K; Kawabata M; Funamizu M; Makita Y; Hata A
Am J Kidney Dis; 2002 May; 39(5):1032-9. PubMed ID: 11979347
[TBL] [Abstract][Full Text] [Related]
9. Thermolabile methylenetetrahydrofolate reductase, homocysteine, and cardiovascular disease risk: the European Concerted Action Project.
Meleady R; Ueland PM; Blom H; Whitehead AS; Refsum H; Daly LE; Vollset SE; Donohue C; Giesendorf B; Graham IM; Ulvik A; Zhang Y; Bjorke Monsen AL;
Am J Clin Nutr; 2003 Jan; 77(1):63-70. PubMed ID: 12499324
[TBL] [Abstract][Full Text] [Related]
10. Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels.
Trinh BN; Ong CN; Coetzee GA; Yu MC; Laird PW
Hum Genet; 2002 Sep; 111(3):299-302. PubMed ID: 12215845
[TBL] [Abstract][Full Text] [Related]
11. MTHFR gene polymorphism, homocysteine and cardiovascular disease.
Cortese C; Motti C
Public Health Nutr; 2001 Apr; 4(2B):493-7. PubMed ID: 11683544
[TBL] [Abstract][Full Text] [Related]
12. Plasma homocysteine levels related to interactions between folate status and methylenetetrahydrofolate reductase: a study in 52 healthy subjects.
Zittoun J; Tonetti C; Bories D; Pignon JM; Tulliez M
Metabolism; 1998 Nov; 47(11):1413-8. PubMed ID: 9826223
[TBL] [Abstract][Full Text] [Related]
13. Premature arterial and venous events in three families. Effect of folate levels and MTHFR mutation mediated by family/generation and homocysteine levels.
Assanelli D; Grassi M; Bonanome A; Salvadori G; Bonetti P; Boldini A; Archetti S; Ruggeri G; Pezzini A; Pagnan A
Thromb Res; 2002 Jan; 105(2):109-15. PubMed ID: 11958800
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of total homocysteine-lowering drugs on cardiovascular disease.
Sunder-Plassmann G; Winkelmayer WC; Födinger M
Expert Opin Investig Drugs; 2000 Nov; 9(11):2637-51. PubMed ID: 11060826
[TBL] [Abstract][Full Text] [Related]
15. Genetic modulation of homocysteinemia.
Rozen R
Semin Thromb Hemost; 2000; 26(3):255-61. PubMed ID: 11011843
[TBL] [Abstract][Full Text] [Related]
16. Anti-epileptic drug treatment in children: hyperhomocysteinaemia, B-vitamins and the 677C-->T mutation of the methylenetetrahydrofolate reductase gene.
Vilaseca MA; Monrós E; Artuch R; Colomé C; Farré C; Valls C; Cardo E; Pineda M
Eur J Paediatr Neurol; 2000; 4(6):269-77. PubMed ID: 11277368
[TBL] [Abstract][Full Text] [Related]
17. Interplay between methylenetetrahydrofolate reductase gene polymorphism 677C-->T and serum folate levels in determining hyperhomocysteinemia in heart transplant recipients.
Potena L; Grigioni F; Viggiani M; Magnani G; Sorbello S; Falchetti E; Sassi S; Mantovani V; Bacchi-Reggiani L; Magelli C; Branzi A
J Heart Lung Transplant; 2001 Dec; 20(12):1245-51. PubMed ID: 11744407
[TBL] [Abstract][Full Text] [Related]
18. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations.
Jacques PF; Bostom AG; Williams RR; Ellison RC; Eckfeldt JH; Rosenberg IH; Selhub J; Rozen R
Circulation; 1996 Jan; 93(1):7-9. PubMed ID: 8616944
[TBL] [Abstract][Full Text] [Related]
19. The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis.
Verhoeff BJ; Trip MD; Prins MH; Kastelein JJ; Reitsma PH
Atherosclerosis; 1998 Nov; 141(1):161-6. PubMed ID: 9863549
[TBL] [Abstract][Full Text] [Related]
20. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients.
Bostom AG; Shemin D; Lapane KL; Nadeau MR; Sutherland P; Chan J; Rozen R; Yoburn D; Jacques PF; Selhub J; Rosenberg IH
Atherosclerosis; 1996 Jun; 123(1-2):193-202. PubMed ID: 8782850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
